February 14, 2023
FDA: Class I recall of Skippack Medical Lab COVID-19 tests
Editor's Note
The Food and Drug Administration (FDA) on February 8 identified the recall by Universal Meditech Inc of its Skippack Medical Lab SARS-CoV-2 Antigen Rapid Test (Colloidal Gold) as Class I, the most serious.
The recall was initiated because the tests were distributed to US customers without authorization, clearance, or approval from the FDA.
Distribution dates were January 2022.
Free Daily News
- Upcoming webinar covers 6 key metrics to improve OR capacity
- Third-party vendors drive healthcare cybersecurity risks
- New guidance: Preoperative GLP-1s safe for surgical patients
- Study: Beta-blockers could increase postoperative stroke risk
- Music therapy reduces opioid use, anxiety in surgical patients
- Study: Poor sleep before surgery boosts risk of postoperative delirium
- GOP-controlled Senate to prioritize drug pricing, health agency reform
- Study links nurse burnout to lower patient safety, care quality
- Private Equity fuels growth of hospital-owned ASCs amidst rising demand, regulatory loopholes
- Outpatient facilities dominate healthcare construction as demand for community-based care grows
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement